Modality
ADC
MOA
IL-13i
Target
APOC3
Pathway
PI3K/AKT
UCCholangiocarcinoma
Development Pipeline
Preclinical
~Apr 2018
→ ~Jul 2019
Phase 1
~Oct 2019
→ ~Jan 2021
Phase 2
Apr 2021
→ Aug 2027
Phase 2Current
NCT08961973
1,141 pts·UC
2021-04→2026-01·Terminated
NCT03404332
2,097 pts·Cholangiocarcinoma
2021-08→2027-08·Active
3,238 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-01-033mo agoNDA· UC
2026-01-282mo agoPh2 Data· UC
2027-08-091.4y awayPh2 Data· Cholangiocarcinoma
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
P2
Termina…
P2
Active
Catalysts
NDA
2026-01-03 · 3mo ago
UC
Ph2 Data
2026-01-28 · 2mo ago
UC
Ph2 Data
2027-08-09 · 1.4y away
Cholangiocarcinoma
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08961973 | Phase 2 | UC | Terminated | 1141 | Mayo |
| NCT03404332 | Phase 2 | Cholangiocarcinoma | Active | 2097 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| AMG-1919 | Amgen | Phase 2/3 | CDK2 |